Acasti Pharma, Inc. (ACST) CEO Janelle D' Alvise on Q1 2020 Results - Earnings Call Transcript [Seeking Alpha]
Acasti Pharma, Inc. - Class A (ACST)
Last acasti pharma, inc. - class a earnings: 2/14 08:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
acastipharma.com/investors
Company Research
Source: Seeking Alpha
Acasti Pharma, Inc. (ACST) CEO Janelle D' Alvise on Q1 2020 Results - Earnings Call Transcript Acasti Pharma, Inc. (NASDAQ: ACST Company Participants David Waldman - Crescendo Communications Janelle D' Alvise - President, CEO, Corporate Secretary & Director Jean-François Boily - VP, Finance Pierre Lemieux - Co-Founder, COO & Chief Scientific Officer Brian Groch - Chief Commercial Officer Conference Call Participants Leland Gershell - Oppenheimer Nathan Weinstein - Aegis Capital Corporation George Zavoico - B. Riley FBR, Inc. Operator Good day, ladies and gentlemen, and thank you all for joining us for this Acasti Pharma First Quarter 2020 Earnings Conference Call. [Operator Instructions]. And now to get us started with opening remarks and introductions, I am pleased to turn the floor to David Waldman, Investor Relations for Acasti Pharma. Welcome, David. [Operator Instructions]. Ladies and gentlemen, I do apologize for the delay and I believe we may have lost connection with our prima
Show less
Read more
Impact Snapshot
Event Time:
ACST
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ACST alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ACST alerts
High impacting Acasti Pharma, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ACST
News
- Acasti Pharma Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACST/price-target/">NASDAQ: ACST</a>) was downgraded by analysts at Zacks Investment Research from a "hold" rating to a "sell" rating.MarketBeat
- Acasti Pharma to Present at the H.C. Wainwright BioConnect 2022 ConferenceGlobeNewswire
- Thinking about buying stock in SeaChange International, American Virtual Cloud Technologies, Quoin Pharmaceuticals, Acasti Pharma, or CohBar?PR Newswire
- Acasti Pharma jumps 21% on new Outperform rating at Oppenheimer with PT of $6 [Seeking Alpha]Seeking Alpha
- Acasti Pharma Inc. (<a href="https://www.marketbeat.com/stocks/NASDAQ/ACST/price-target/">NASDAQ: ACST</a>) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $6.00 price target on the stock.MarketBeat
ACST
Sec Filings
- 12/2/21 - Form 8-K
- 11/23/21 - Form 3
- 11/16/21 - Form 4
- ACST's page on the SEC website